Cargando…
Steroid-free medium discloses oestrogenic effects of the bisphosphonate clodronate on breast cancer cells
Tamoxifen is the standard first-line endocrine therapy for breast cancer, but recent data indicate that it is likely to be replaced by the effective aromatase inhibitors (AIs), in both the metastatic and adjuvant settings. Aromatase inhibitors induce complete oestrogen deprivation that leads to clin...
Autores principales: | Journe, F, Chaboteaux, C, Dumon, J-C, Leclercq, G, Laurent, G, Body, J-J |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409948/ https://www.ncbi.nlm.nih.gov/pubmed/15477866 http://dx.doi.org/10.1038/sj.bjc.6602181 |
Ejemplares similares
-
Biological response to hormonal manipulation in oestrogen receptor positive ductal carcinoma in situ of the breast
por: Boland, G P, et al.
Publicado: (2003) -
The influence of tamoxifen treatment on the oestrogen receptor in metachronous contralateral breast cancer
por: Kaas, R, et al.
Publicado: (2003) -
Expression of oestrogen receptor beta (ERβ1) protein in human breast cancer biopsies
por: Saunders, P T K, et al.
Publicado: (2002) -
Extracellular calcium increases bisphosphonate-induced growth inhibition of breast cancer cells
por: Journé, Fabrice, et al.
Publicado: (2008) -
Relationship of coregulator and oestrogen receptor isoform expression to de novo tamoxifen resistance in human breast cancer
por: Murphy, L C, et al.
Publicado: (2002)